Population pharmacokinetic-pharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: Dosing considerations for Acinetobacter baumannii infections

Journal of Infection and Chemotherapy

Volumn 21, Issue 4, 2015, Pages 284-289

  Yokoyama, Yuta ^a,b   Matsumoto, Kazuaki ^a   Ikawa, Kazuro ^b   Watanabe, Erika ^a   Morikawa, Norifumi ^b   Takeda, Yasuo ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Acinetobacter baumannii; Dosing regimen; Monte carlo simulation; Population pharmacokinetics; Sulbactam

Indexed keywords

AMPICILLIN; SULBACTAM; ANTIINFECTIVE AGENT;

ACINETOBACTER INFECTION; ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BLOOD SAMPLING; CHEMICAL ANALYSIS; CLINICAL ASSESSMENT; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; FEMALE; HUMAN; KIDNEY CLEARANCE; KIDNEY CONCENTRATING CAPACITY; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NON-RENAL CLEARANCE; PHARMACODYNAMICS; POPULATION; URINALYSIS; URINARY EXCRETION; VOLUME OF DISTRIBUTION; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; BIOLOGICAL MODEL; BLOOD; DRUG EFFECTS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOPHYSIOLOGY; URINE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; RENAL INSUFFICIENCY; SULBACTAM;

EID: 84930378566     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2014.12.005     Document Type: Article

References (22)

1. Maragakis L.L., Perl T.M. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008, 46:1254-1263.
2. Sieniawski K., Kaczka K., Rucińska M., Gagis L., Pomorski L. Acinetobacter baumannii nosocomial infections. Pol Przegl Chir 2013, 85:483-490.
3. Corbella X., Ariza J., Ardanuy C., Vuelta M., Tubau F., Sora M., et al. Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. JAntimicrob Chemother 1998, 42:793-802.
4. Drusano G.L. Prevention of resistance: a goal for dose selection for antimicrobialagents. Clin Infect Dis 2003, 36(Suppl.1):S42-S50.
5. Soto E., Shoji S., Muto C., Tomono Y., Marshall S. Population pharmacokinetics of ampicillin and sulbactam in patients with community-acquired pneumonia: evaluation of impact of renal impairment. Br J Clin Pharmacol 2014, 77:509-521.
6. Jaruratanasirikul S., Wongpoowarak W., Aeinlang N., Jullangkoon M. Pharmacodynamics modeling to optimize dosage regimens of sulbactam. Antimicrob Agents Chemother 2013, 57:3441-3444.
7. Yokoyama Y., Matsumoto K., Ikawa K., Watanabe E., Shigemi A., Umezaki Y., et al. Pharmacokinetic and pharmacodynamic evaluation of sulbactam against Acinetobacter baumannii in invitro and murine thigh and lung infection models. Int J Antimicrob Agents 2014, 43:547-552.
8. Martin C., Cotin A., Giraud A., Beccani-Argeme M., Alliot P., Mallet M.N., et al. Comparison of concentrations of sulbactam-ampicillin administered by bolus injections or bolus plus continuous infusion in tissues of patients undergoing colorectal surgery. Antimicrob Agents Chemother 1998, 42:1093-1097.
9. Sekine O., Usuda Y., Aoki N., Yuasa Y., Kohda Y. Clinical study of sulbactam ampicillin. Jpn J Chemother 1988, 36:130-136.
10. Yura J., Shinagawa N., Mizuno A., Mashita K., Taniguchi M., Hori K., et al. Basic and clinical studies on sulbactam ampicillin in the surgical field. Jpn J Chemother 1988, 36:324-333.
11. Ohta N., Morinaga O., Hirai M., Yamaguchi Y., Ushiyama T., Tama A., et al. Clinical and pharmacokinetic studies on sulbactam ampicillin. Jpn J Chemother 1988, 36:382-394.
12. Cho N., Fukunaga K., Katsuaki Kunii, Kimura T., Saito Y., Suzuki A., et al. Basic and clinical studies on sulbactam ampicillin in obstetrics and gynecology. Jpn J Chemother 1988, 36:466-489.
13. Yokoyama Y., Matsumoto K., Yamamoto H., Iguro Y., Imoto Y., Ikawa K., et al. Pharmacokinetics of ampicillin-sulbactam and the renal function-based optimization of dosing regimens for prophylaxis in patients undergoing cardiovascular surgery. JInfect Chemother 2012, 18:878-882.
14. Shimooka K., Ito M., Matsumoto K., Niimi H., Matsunaga T., Kawasaki K. Sensitive high-performance liquid chromatographic-amperometric and microbiological assays for determining sulbactam in serum. Jpn J Chemother 1988, 36:81-89.
15. Kano H., Sekiguchi K., Takematsu K., Shimooka K., Oki T. Assay methods of sulbactam and cefoperazone in body fluids and tissues. Jpn J Chemother 1988, 32:131-141.
16. Ikawa K., Morikawa N., Uehara S., Monden K., Yamada Y., Honda N., et al. Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients. Int J Antimicrob Agents 2009, 33:276-279.
17. Wayne P.A. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard 8th ed 2009, Clinical and Laboratory Standards Institute, Document M7-A8.
18. Trotman R.L., Williamson J.C., Shoemaker D.M., Salzer W.L. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 2005, 41:1159-1166.
19. De la Pena A., Derendorf H. Pharmacokinetic properties of beta-lactamase inhibitors. Int J Clin Pharmacol Ther 1999, 37:63-75.
20. Oliveira M.S., Prado G.V., Costa S.F., Grinbaum R.S., Levin A.S. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. JAntimicrob Chemother 2008, 61:1369-1375.
21. Fishbain J., Peleg A.Y. Treatment of Acinetobacter infections. Clin Infect Dis 2010, 51:79-84.
22. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998, 26:1-10.